THE REAL ALEX JONES | PART 2

Del just got back from Washington, DC, and this Episode of The HighWire is loaded.

The MAHA Institute held one of the most important conversations on vaccine injury Del says he’s ever seen. The panels were extraordinary, the science is no longer being buried, and the discussion is going global. Bottom line: autism is not a mystery. Is the gaslighting is on its way out?

RFK Jr. was also in DC, pushing his “Eat Real Food” campaign – and Del thinks it’s spectacular.

Meanwhile, a major shakeup inside HHS. Vinay Prasad is out. What does that mean? We break it down.

Plus, Tracy Slepcevic joins the show. She sits on the IACC – the Interagency Autism Coordinating Committee – and she’s the parent of a child with autism. Real parents are now at the table inside of HHS. What a change! We will talk with her about what that means, and more.

And, The HighWire is cooking… Literally. Chef Aran Goldstein has been transforming school lunch programs across the country, and he is bringing it to the studio.

Don’t miss The HighWire, Episode 467, TOMORROW!

📅March 12, 2026
⏰Thursday, 11AM PT | 2PM ET
📺Watch at: TheHighWire.com/WATCH

The HighWire coverage of MAHA Institute Round Table focusing on the “Massive Epidemic of Vaccine Injury (MEVI)”, brings together experts, researchers, physicians, and policy leaders to discuss emerging evidence, patient experiences, and the broader implications for public health policy. The discussion aims to examine concerns surrounding vaccine safety, injury reporting, regulatory oversight, and the role of government institutions in monitoring adverse events.

Throughout the event, speakers will discuss the scientific, medical, and legal dimensions of vaccine injury claims, the current systems for reporting and compensation, and what policy changes may be needed moving forward. The goal is to foster open dialogue and bring greater public awareness to questions surrounding vaccine safety and regulatory decision-making.

A tense Senate hearing places physician and health advocate Casey Means in the spotlight as Senator Bill Cassidy presses her on measles outbreaks, vaccine policy, and whether parents should vaccinate their children. The exchange highlights the growing political pressure surrounding public health guidance and the widening divide over how doctors discuss risk, vaccine recommendations, and informed consent.

Del Bigtree explains why the moment extends far beyond a single Senate hearing. As debates intensify over vaccine safety, pharmaceutical protections, and government health authority, the exchange reflects a broader shift unfolding across medicine, politics, and public discourse.

With trust in health institutions continuing to decline and more Americans demanding transparency in medical policy, the discussion points to a pivotal moment in the national conversation about patient choice, medical freedom, and the future of public health.

AIRDATE: March 5, 2026

The White House is shaking up the vaccine world again — this time over aluminum. In this Episode 466 interview, Del Bigtree sits down with Brian Hooker, PhD, and board-certified emergency and integrative physician James Neuenschwander, MD, to unpack their landmark 2026 paper: “Aluminum Adjuvants, Autoimmunity and Autism Spectrum Disorder: A Comprehensive Mechanistic, Neuropathological and Legal Analysis.”

The paper reviewed approximately 700 references to build a mechanistic case connecting aluminum nanoparticle adjuvants in childhood vaccines to immune activation, NLRP3 inflammasome-driven neuroinflammation, mitochondrial damage, disrupted synaptic pruning, and the development of autism spectrum disorder. Hooker and Neuenschwander walk through the biological pathway step by step — from injection site to white blood cell uptake to brain trafficking — and explain how they applied all nine Bradford Hill criteria to argue for causation rather than mere correlation.

The conversation also covers why aluminum nanoparticles in vaccines behave differently from dietary aluminum, the role of autoimmune encephalitis found in 64% of autistic brain autopsy studies, the cumulative aluminum load from the current childhood vaccine schedule, and what changing adjuvants or restructuring the schedule could mean. Dr. Hooker shares why he considers this the most important work of his career, and both guests discuss the broader scientific and political debate around vaccine safety under the current HHS administration.

AIRDATE: March 5, 2026

ICAN lead attorney Aaron Siri joins Del Bigtree following his appearance on The Joe Rogan Experience, where millions of listeners heard his legal arguments surrounding vaccine safety studies and the policies governing the childhood immunization schedule.

During the widely discussed interview, Siri outlined how federal laws such as the National Childhood Vaccine Injury Act of 1986 shaped the legal framework around vaccine manufacturers and injury claims, sparking renewed debate about accountability and safety oversight.

The conversation also turns to a letter sent to Siri by renowned vaccinologist Dr. Stanley Plotkin, often referred to as the “godfather of vaccines,” criticizing Siri’s work and warning that it contributes to vaccine hesitancy.

Siri reads from his response and revisits the highly publicized 2018 deposition of Dr. Plotkin, where he questioned the leading vaccine scientist for nearly ten hours about vaccine testing, research ethics, and safety science.

The discussion revisits the scientific and legal foundations of modern vaccinology and examines why the debate over vaccine safety, informed consent, and pharmaceutical accountability continues to gain national attention.

AIRDATE: March 5, 2026

The global vaccine market may be entering a pivotal turning point. Investigative journalist Jefferey Jaxen examines the rapid decline in vaccine demand across the United States and worldwide, as major pharmaceutical companies report falling sales for vaccines targeting RSV, influenza, shingles, COVID-19, and HPV (Gardasil).

At the same time, vaccination rates are declining in several U.S. states—including California—while global vaccine revenues show signs of contraction after the pandemic-era surge. These trends are fueling renewed debate about pharmaceutical liability protections created under the National Childhood Vaccine Injury Act of 1986, which shields vaccine manufacturers from most direct lawsuits.

Critics argue that legal immunity for vaccine manufacturers may have reduced incentives to improve product safety and transparency. As public scrutiny grows following the COVID-19 pandemic, calls to revisit vaccine liability protections are gaining traction across the political spectrum.

With Robert F. Kennedy Jr. now leading the U.S. Department of Health and Human Services (HHS) and bipartisan discussion emerging around pharmaceutical accountability, the future of vaccine policy may be approaching a significant inflection point.

This analysis explores the economic slowdown in the vaccine market, the history and impact of liability protections for pharmaceutical companies, and the growing public debate over how to rebuild trust in vaccines, regulators, and the medical system.

AIRDATE: March 5, 2026

Public trust in government may be eroding—but one issue appears to be uniting voters across party lines: pharmaceutical liability protections. Jefferey Jaxen examines new polling showing a majority of both Republicans and Democrats support removing legal immunity for vaccine manufacturers.

The findings challenge long-standing policies such as the National Childhood Vaccine Injury Act of 1986, which shields vaccine makers from most direct lawsuits, and the PREP Act, which extended liability protections during the COVID-19 pandemic.

At the same time, vaccine-related legislation is rapidly expanding across the United States. More than 825 vaccine-related bills have been introduced in 2026, reflecting a growing national debate over vaccine policy, medical freedom, and government transparency.

With upcoming ACIP meetings expected to address COVID-19 vaccine injury concerns, ongoing global disputes over vaccine compensation programs, and new state laws that could shift liability to governments instead of manufacturers, the issue of pharmaceutical immunity is receiving renewed scrutiny.

This report explores how shifting public opinion, expanding legislation, and renewed calls for accountability could reshape the future of vaccine policy, pharmaceutical liability, and public trust in health institutions.

AIRDATE: March 6, 2026

While global conflicts dominate headlines, a major public health story may be unfolding quietly in the U.S. Supreme Court. Del Bigtree breaks down the Trump administration’s Department of Justice decision to support Bayer/Monsanto in a critical legal case that could limit lawsuits over the weedkiller glyphosate—best known as the active ingredient in Roundup.

The case centers on whether pesticide manufacturers can be held liable for failing to warn consumers about potential cancer risks. Bayer is seeking protection from thousands of lawsuits linking glyphosate exposure to non-Hodgkin’s lymphoma, arguing that federal regulatory approvals should preempt state-level failure-to-warn claims.

Glyphosate is one of the most widely used herbicides in the world and is sprayed on an estimated 80–90% of major U.S. crops, making the outcome of the case potentially significant for farmers, consumers, and the future of food safety regulation.

Supporters of Bayer argue that uniform federal labeling standards are necessary for agricultural stability, while critics warn the case could weaken corporate accountability and limit Americans’ ability to pursue legal action against pesticide manufacturers.

As the legal battle unfolds, this discussion explores the implications for glyphosate litigation, corporate liability, EPA oversight, food safety policy, and the future of regenerative agriculture in the United States.

AIRDATE: March 5, 2026

The HighWire with Del Bigtree — Episode 466 (March 5, 2026) opens with breaking legal and policy news: the Trump EPA has filed a brief at the U.S. Supreme Court backing Bayer/Monsanto and glyphosate (Roundup). Del breaks down what the government is arguing, what’s at stake for warning labels and litigation, and why the outcome could reshape corporate accountability around glyphosate-based herbicides.

Then, Jefferey Jaxen covers the accelerating shift in public vaccine sentiment, as global vaccine uptake declines and pharmaceutical stocks react to falling demand. Del analyzes the latest reported data, including a major worldwide drop in Gardasil (HPV vaccine) uptake, and what these trends could signal for vaccine policy, mandates, and the future of the vaccine marketplace.

Also, a dive into the growing national debate over vaccine manufacturer liability. New polling indicates strong public support for restoring legal accountability for vaccine makers, a key issue tied to vaccine injury protections, medical freedom, and federal vaccine policy.

Plus, an in-studio scientific discussion you don’t want to miss: Del is joined by Dr. James Neuenschwander and Dr. Brian Hooker to break down a new study examining aluminum in vaccines and the potential implications for vaccine safety research, adverse event risk, and the broader childhood vaccination schedule.

Watch The HighWire live on TheHighWire.com, then catch the full archived episode on-demand right here.